Latest research
Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Rheumatology · Ann Rheum Dis · 2026-08-07
RCTn = 670
van der Heijde et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trialDermatology · Br J Dermatol · 2026-07-17
RCTn = 94
King et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trialRheumatology · Ann Rheum Dis · 2026-05-12
Secondary analysisn = 363
Vital et al. Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial